Brickell Enters into a License Agreement for Exclusive Rights to BBI-3000, a Novel, Potent Topical/Oral Retinoid, Acting as a Highly Selective RXR Agonist, for the Treatment of Skin Conditions Responsive to Retinoid Therapy
We use first and third party cookies to obtain statistical information to personalize our website and provide you with a better experience. If you continue without changing your settings, this demonstrates your consent to receive all cookies or other tracking technologies on the Brickell Biotech website for the purposes described in our Cookie
Policy. Please know that you can change your cookie settings at any time in your browser settings.. Cookie settingsACCEPT
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.